Expert Andrew Lipsky, MD, reviews a patient case of relapsed/refractory chronic lymphocytic leukemia managed with BTK inhibition in the second-line setting.
A 72-Year-Old Male with R/R Chronic Lymphocytic Leukemia
Focused discussion on the first-line treatment armamentarium available to patients diagnosed with chronic lymphocytic leukemia.
Andrew Lipsky, MD, considers the role of BTK inhibitors as second-line therapy in patients with relapsed/refractory chronic lymphocytic leukemia.
Expert perspectives on the ALPINE trial of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Shared insight on ELEVATE-RR, which utilized acalabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Centering conversation on patients with relapsed/refractory chronic lymphocytic leukemia, Andrew Lipsky, MD, reviews efficacy data and considers how it impacts treatment selection.
Comprehensive insight to cardiovascular safety data with available therapies and how current understandings may impact the management of patients with relapsed/refractory chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
